Claudio Scangiuzzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Claudio Scangiuzzi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Aimo
Health Sciences Interdisciplinary Center, Scuola Superiore Sant’Anna , piazza Martiri della Libertà 33, 56127 Pisa
1 shared publication - Anna Merlo
School of Medicine and Surgery, University of Milan-Bicocca, 20126 Milan, Italy
1 shared publication - Edoardo Sciatti
Cardiology Unit 1, ASST Papa Giovanni XXIII, Bergamo, Italy
1 shared publication - Emilia D’elia
Cardiology Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy
1 shared publication - Giuseppe Vergaro
Health Science Interdisciplinary Center, Scuola Superiore Sant’Anna, Pisa, Italy
1 shared publication - Mauro Gori
Cardiology Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy
1 shared publication
Latest Publications
- Open Access
- 11 June 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (12) , 3970
Prognostic Value of sST2 in Heart Failure
In recent years, there has been growing interest in the risk stratification for heart failure, and the use of multiple biomarkers to identify different pathophysiological processes associated with this condition. One such biomarker is soluble suppression of tumorigenicity-2 (sST2), which has shown some potential for integration into clinical practice. sST2 is produced by both cardiac fibroblasts and cardiomyocytes in response to myocardial stress. Other sources of sST2 are endothelial cells of the aorta and coronary arteries and immune cells such as T cells. Indeed, ST2 is also associated with inflammatory and immune processes. We aimed at reviewing the prognostic value of sST2 in both chronic and acute heart failure. In this setting, we also provide a flowchart about its potential use in clinical practice.
- 11 June 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (12) , 3970
Open AccessPrognostic Value of sST2 in Heart Failure
In recent years, there has been growing interest in the risk stratification for heart failure, and the use of multiple biomarkers to identify different pathophysiological processes associated with this condition. One such biomarker is soluble suppression of tumorigenicity-2 (sST2), which has shown some potential for integration into clinical practice. sST2 is produced by both cardiac fibroblasts and cardiomyocytes in response to myocardial stress. Other sources of sST2 are endothelial cells of the aorta and coronary arteries and immune cells such as T cells. Indeed, ST2 is also associated with inflammatory and immune processes. We aimed at reviewing the prognostic value of sST2 in both chronic and acute heart failure. In this setting, we also provide a flowchart about its potential use in clinical practice.